Collaboration Agreements Teva Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Sep. 30, 2016	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues		$ 1,608,022		$ 1,470,116	$ 3,119,507	$ 2,789,107
Teva Pharmaceuticals Collaboration Agreement [Member]
Disaggregation of Revenue [Line Items]
Up-front payment received	$ 250,000
Revenue recognition, milestone method, revenue recognized			$ 35,000	25,000
Aggregate future development milestone payments the Company is eligible to receive					400,000
Collaborative arrangement, additional eligible aggregate payments					1,890,000
Revenues		68,800		$ 67,700	127,400	$ 100,800
Remaining performance obligation		$ 525,300			$ 525,300